Carlo Visco, MD

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Carlo Visco, MD, explains the need to study treatment outcomes and develop novel therapies for patients with mantle cell lymphoma harboring TP53 mutations.

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Carlo Visco, MD, discusses the utility of bendamustine-based regimens in mantle cell lymphoma.

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.